Causes and consequences of obesity: epigenetics or hypokinesis?

Dear editor

Epigenetics can be defined as the study of heritable changes that affect gene function without modification of the deoxyribonucleic acid (DNA) sequence. The transfer of epigenetic marks through generations is not well understood, and their transmission is in dispute. Epigenetic marks are tissue-specific and include DNA methylation and histone modifications that mediate biological processes, such as imprinting (Figure 1). Many imprinted genes are regulators of gene expression controlling growth. Imprinting disorders often feature obesity as one of their characteristics.

Genomic imprinting determines expression of alleles, creating an equilibrium between the expression of the parental alleles influencing growth and metabolism. The identification of susceptible loci, and finding the causal genes and variants in each locus for obesity may allow molecular and physiological investigations. However, the knowledge of the mechanisms through which these contribute to susceptibility to obesity will not necessarily provide the requisite management strategies.

Geneticists have long since identified the obesity gene (FTO) and a low-fat gene (APOA5), and that variations in the adiponectin gene (single nucleotide polymorphism [SNP] 276 G allele) can lead to hypoadiponectinemia, which then results in insulin resistance, the metabolic syndrome, increased atherosclerosis, morbidity, and ultimately, premature mortality. Using exome sequencing, a low-frequency coding variant has been identified in the SYPL2 gene associated with morbid obesity. This gene may be involved in the development of excess body fat.

Hypokinesis, in conjunction with excess caloric intake over expenditure, leads to obesity, which can then result in the metabolic syndrome, type 2 diabetes mellitus, cardiovascular disease (CVD), coronary heart disease, and cerebrovascular accident, or “stroke”. Obesity is also believed to predispose to certain types of cancer, such as breast and colon cancer.

However, the assertion that the complete absence of fat cells (adipocytes) is metabolically advantageous is a fallacy. Adipocytes play an important role in health by their hormonal role in the regulation of energy intake and fat storage, and function as an endocrine gland (Figure 2). Adipocytes secrete approximately 50 adipokines with diverse functional roles.

The average human phenotype contains 30 billion fat cells, weighing approximately 13.5 kg. To establish the dynamics within the stable population of adipocytes in...
adults, adipocyte turnover can be measured by analyzing the integration of $^{14}$C derived from nuclear bomb tests in genomic DNA. If excess weight is gained as an adult, fat cells increase approximately fourfold in size before dividing and increasing the absolute number of fat cells present. However, even after marked weight loss, the number of fat cells stays constant in adulthood in lean and obese individuals, indicating that the number of adipocytes is set during childhood and adolescence.\textsuperscript{19} Approximately 10% of fat cells die and are replaced annually. The expansion of the fat cell population and the final number of adipocytes in the adult body appears to occur at an earlier age in obese people. Fatter people experience a period of rapid adipocyte production around the age of 2 years and reach their adult number of fat cells when they are approximately 16.5 years old.\textsuperscript{19} Lean people, however, recruit fat cells most rapidly at approximately 6 years old, with their fat cell population reaching its adult size at approximately 18.5 years. Obese people have as many as twice the number of adipocytes as lean people.\textsuperscript{19}

Scientific evidence supports the concept that gene expression in our physically active ancestors reduced adverse physiological effects that may occur with a sedentary lifestyle. To prevent the development of these adverse physiological effects, children who experience appropriate nutrition and regular exercise during their growing years display healthy patterns of physical maturation consistent with their genetic potential.\textsuperscript{20} However, a genetic explanation cannot explain how humans have become so fat over such a short time frame.\textsuperscript{21} Heredity can only explain 67% of the population variance in obesity.\textsuperscript{22} Genetics are unlikely to account fully for the prevalence of obesity – it must be due to the declining rates of physical activity and an increase in the consumption of energy-dense foods.\textsuperscript{23,24} The differences in phenotypes and physiology between two geographically separate but genetically similar Pima Indian tribes suggests the importance of the environmental effect, especially physical activity, on the genome.\textsuperscript{25} The Mexican Pima Indians were found to expend 2,100–2,520 kJ day$^{-1}$ more in physical activity than did their obese Arizonian Pima equivalents, to have had a diet lower in fat and higher in fiber content, and to weigh 26 kg less.\textsuperscript{25} As a consequence, the
Mexican Pima Indians did not have the diabetes prevalence of the Arizonian Pima Indians.\textsuperscript{26}

Children of pregnant women exposed to the Dutch famine of 1944 were more susceptible to diabetes, obesity, CVD, renal disease, and other health problems.\textsuperscript{27} The children of the women who were pregnant during the famine were smaller, and when these children grew up and had children, those children were also smaller than average.\textsuperscript{28} This suggested that the famine experienced by the mothers caused epigenetic changes that were passed down to the next generation.

Genetic predisposition is the primary cause of most of the rare diseases that affect one in 17 people.\textsuperscript{29,30} Every human possesses approximately three million sequence variants of which approximately 400 can predispose to pathology, in adverse environmental circumstances.\textsuperscript{31}

Could lifestyle assessments and avoidance of potential risks have beneficial effects on a person’s health despite genetic variants? This question can only truly be answered if we are able to sequence individual genomes on demand and then, only if it is cost effective.

The general public should be concerned with prevention rather than the management of obesity and its sequelae. Despite considerable financial investment, the pharmaceutical industry has provided only palliation of obesity rather than cure.

Physical activity should be the main agenda of the Department of Health and the responsibilities for its effective prescription and assessments placed in the hands of appropriate health professionals. More consideration should be given to effective exercise prescription rather than the premature introduction of prescription medicines, such as the latest insulin analog or glucagon-like peptide-1 agonist (GLP-1 agonist), to type 2 diabetics, which appears to be only palliating the disease state and elevating the public purse’s annual budget.\textsuperscript{32}

In the UK in 1998 the anti-obesity drugs’ bill was £20,000.00 and in 2005 it was £38 million, with increased prescribing of drugs such as orlistat and sibutramine.\textsuperscript{33} In 2010 it was £50 million.\textsuperscript{34}

The annual drugs bill in the UK is currently around £12 billion, which equates to just approximately 10% of National Health Service (NHS) expenditure, having risen around 3.5% a year between 2007 and 2013.

When the NHS was launched in 1948 it had a budget of £437 million (circa £9 billion at today’s value). For 2015 it is predicted to be £115.4 billion.\textsuperscript{35}

The obesity epidemic that we are experiencing is a global phenomenon. In 2005 more than 1.6 billion adults over the age of 15 years, were overweight and 400 million were obese. By 2015 it has been predicted that more than 2.3 billion

---

**Figure 2** The endocrine function of an adipocyte.

**Abbreviations:** NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; PAI-1, plasminogen activator inhibitor-1; TNF, tumor necrosis factor.
adults over the age of 15 years, will be overweight and at least 700 million will be obese. With global projections, more than 2.16 billion will be overweight and 1.12 billion will be obese individuals by 2030.

Watson and Crick discovered the structure of DNA in 1953, and Sanger identified the amino acid sequence of insulin in 1955, and nucleic acid sequencing becoming a major target of early molecular scientists.

However, we are no nearer to eradicating the most basic of diseases, associated with obesity.

Have we really had a single or series of genetic mutations to account for a 21.4% and a 24% increase in obesity in males and females respectively, in a mere third of a century?

Sequencing the first human genome took 13 years and was completed in 1986 at a cost of £2 billion. Today we can sequence a complete human genome in two days at a cost of approximately £4,000.00.

Bulk sequencing all 20–25,000 human protein coding genes, the exome, now costs less than £500.

Targeting the screening of a specific panel of genes known to be associated with a particular phenotype, as opposed to screening mutations, would appear necessary in the belief that eating five pieces of fruit and vegetables a day will keep us slim, healthy, and disease free. Scientists are required to identify variants in genes, known to be pathogenic in an effort to decide on preventative, curative or palliative action.

The investment continues as the government’s decision to gene sequence 100,000 whole genomes at a cost to the public purse of £100 million hoping to identify the reason for the current obesity pandemic, pursuant to the work of the Wellcome Trust’s Sanger Institute initiating the Human Genome Project. However, will such an investment stimulate the general population to cease eating refined processed foods and commence exercising?

The fact there is so much money available for such a resource is surprising. Should not that money be available to employ more exercise scientists, who can advise these obese phenotypes that eating the correct diet and performing even limited amounts of exercise can bring about positive transgenerational epigenetic changes to the major CVD risk factors.

Currently the vast sums of money spent in researching pharmacotherapy alone appear to be having very little effect. A greater investment should be applied to promoting exercise in conjunction with exome sequencing and epigenetic research.

Human growth hormone (hGH) which controls the body’s ability to metabolize carbohydrate, fat, and protein and deposit any excess fat in the appropriate site, commences a downward spiral, after full adult growth has been attained. It decreases by 14% per decade from the age of 20 years. Exercising for more than 10–20 minutes at an oxygen uptake (VO_max) of 70%, stimulates pituitary release of hGH by five- to tenfold. Protein consumption stimulates pituitary release of hGH. Carbohydrate and fat ingestion inhibit pituitary release of hGH. Also obesity causes a blunted response to hGH compounding the adverse situation.

Physical activity can ultimately prevent many problems associated with obesity. There is a lower cancer incidence rates among the adult Amish population, compared with non-Amish population, due to increased physical activity. Physical activity differences can be identified in childhood in the Amish compared with non-Amish population and accounts for Amish children being approximately 3.3 times less likely to be overweight compared to non-Amish children. The average American would aspire to walk approximately 10,000 steps per day to maintain a healthy body mass. In one study the average number of steps walked per day was 18,425 for Amish men versus 14,196 for Amish women, who have a very low incidence of obesity. The Old Order Amish refrain from driving cars, using electrical appliances, and employing other modern conveniences. Labor-intensive farming is still the preferred occupation.

**Conclusion**

Obesity is a consequence of a high saturated fat, a refined carbohydrate diet, and an increased input over expenditure, combined with reduced exercise. Proactive research scientists are working to identify explanations, at the molecular level, relating exercise to health improving epigenetic changes. Prevention must always be better than cure. When a large segment of the population adopts modest improvements in health behaviors, the overall disease burden in the population is likely to be reduced more dramatically than if a modest segment of the population adopts large changes.

**Disclosure**

The authors report no conflicts of interest in this communication.

**References**

1. Bird A. Perceptions of epigenetics. *Nature*. 2007;447(7143):396–398.
2. Chong S, Younson NA, Whitelaw E. Heritable germline epimutation is not the same as transgenerational epigenetic inheritance. *Nat Genet*. 2007;39(5):574–575; author reply 575.
3. Herrera BM, Keildson S, Lindgren CM. Genetics and epigenetics of obesity. *Maturitas*. 2011;69(1):41–49.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8

28. Painter RC, Osmond C, Gluckman P, Hanson M, Phillips DI, Roseboom TJ. Exome sequencing followed by genotyping suggests SYPL2 as a susceptibility gene for morbidity obesity. *Eur J Hum Genet*. Epub 2014 Nov 19.

29. Xue Y, Chen Y, Ayub Q, et al; 1000 Genomes Project Consortium. A SNP in the adiponectin gene is associated with decreased serum adiponectin levels and for impaired glucose tolerance. *Obes Res*. 2005;13(5):807–812.

30. Jiao H, Arner P, Gerdhem P, et al. Exome sequencing followed by genotyping suggests SYPL2 as a susceptibility gene for morbidity obesity. *Eur J Hum Genet*. Epub 2014 Nov 19.

31. Xue Y, Chen Y, Ayub Q, et al; 1000 Genomes Project Consortium. A SNP in the adiponectin gene is associated with decreased serum adiponectin levels and for impaired glucose tolerance. *Obes Res*. 2005;13(5):807–812.

32. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. *Cochrane Database Syst Rev*. 2004;3:CD004094.

33. Dramatic rise in slimming drugs prescriptions leaves NHS with £50 m bill. *The Daily Mail*. 2010 Sept 20. Available from: http://www.dailymail.co.uk/health/article-1131362/Slimming-drugs-cost-NHS-50m.html. Accessed January 3, 2015.

34. Watson JD, Crick FH. A structure for deoxyribonucleic acid. *Nature*. 1953;171(4356):737–738.

35. Stroten AOW. The first sequence. Fred Sanger and insulin. Genetics. 2002;162(2):527–532.

36. Flinter F. Should we sequence everyone’s genome? *No. BMJ*. 2013;346:f3132.

37. Watson JD, Crick FH. An amino acid sequence. *Nature*. 1958(175):737–738.

38. Wright CF, Middleton A, Burton H, et al. Policy challenges of clinical genome sequencing. *BMJ*. 2013;347:f6845.

39. Buchan DS, Young JD, Boddy LM, Baker JS. Independent associations between cardiorespiratory fitness, waist circumference, BMI, and clustered cardiometabolic risk in adolescents. *Am J Hum Biol*. 2014;26(1):29–35.

40. Denham J, Marques FZ, O’Brien BJ, Charchar FJ. Exercise: putting action into our genome. *Sports Med*. 2014;44(2):189–209.

41. Iranmanesh A, Lizarreda G, Veldhuis JD. Exercise: putting action into our genome. *Sports Med*. 2014;44(2):189–209.

42. Miao H, Leinster S, Bunsley S, et al. Transcriptional changes underlie diet-induced fatty liver susceptibility and gene expression: physiological regulation of the human genome through thermogenic function in cultured primary brown and brite/beige adipocytes. *EMBO Rep*. 2014;15(10):1053–1054.

43. Anderson AS, Caswell S. Obesity management—an opportunity for transgenerational effects of prenatal exposure to the Dutch famine on neonatal and overweight. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2012;9(6):1022–1032.

44. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with adult body mass index and predisposes to childhood and adult obesity. *Science*. 2007;316(5826):889–894.

45. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. *Am J Clin Nutr*. 2006;83(2):461S–465S.

46. Root AW, Root MJ. Clinical pharmacology of human growth hormone (GH)-releasing hormone-mediated GH secretion in man. *J Clin Endocrinol Metab*. 1998;83(6):1867–1879.

47. Spalding KL, Arner E, Westmark PO, et al. Dynamics of fat cell turnover in humans. *Nature*. 2008;453(7196):783–787.

48. Booth FW, Chakravarty MV, Spangenberg EG. Exercise and gene expression: physiological regulation of the human genome through physical activity. *J Physiol*. 2002;543(Pt 2):399–411.

49. Toye AA, Dumas ME, Blancher C, et al. Subtle metabolic and liver gene transcriptional changes underlie diet-induced fatty liver susceptibility in insulin-resistant mice. *Diabetologia*. 2007;50(9):1867–1879.

50. Brownson RC, Boehmer TK, Luke DA. Declining rates of physical activity in the United States: what are the contributors? *Ann Rev Public Health*. 2005;26:421–443.

51. Li Z, Bowerman S, Heber D. Health ramifications of the obesity epidemic. *Surg Clin North Am*. 2005;85(4):681–701, v.

52. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. *Nature*. 2006;444(7121):875–880.

53. Kahn HS. Obesity and risk of myocardial infarction: the INTERHEART study. *Lancet*. 2006;367(9516):1053–1054.

54. Anderson AS, Caswell S. Obesity management—an opportunity for transgenerational effects of prenatal exposure to the Dutch famine on neonatal and overweight. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2012;9(6):1022–1032.

55. Scholz GH, Fleischmann H. Basal insulin combined incretin mimetic therapy with glugagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. *Ther Adv Endocrinol Metab*. 2014;5(5):95–123.

56. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. *Cochrane Database Syst Rev*. 2004;3:CD004094.

57. Watson JD, Crick FH. A structure for deoxyribonucleic acid. *Nature*. 1953;171(4356):737–738.
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.